Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (61-70 of 239) with videos related to

Pageof 24
Sort By:
Cancer Chemotherapy and Pharmacology|January 26, 2019
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancerKathleen Moore, John K Chan, Angeles Alvarez Secord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 14, 2013
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancerAngeles Alvarez Secord, Jason Cory Barnett, Jonathan A Ledermann, et al.
Cancer|August 8, 2013
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancerJason C Barnett, Angeles Alvarez Secord, David E Cohn, et al.
Gynecologic Oncology|September 28, 2018
Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysisStephanie L Lim, Haley A Moss, Angeles Alvarez Secord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2024
Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort studyNguyen Thao Thi Nguyen, Nicole Diaz, Hadley Reid, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 24, 2018
Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care ReferralsJonathan Foote, Micael Lopez-Acevedo, Gregory Samsa, et al.
Gynecologic Oncology|April 22, 2004
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancerLaura J Havrilesky, Charles A Leath, Warner Huh, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|May 14, 2023
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry scoreJulia M Moyett, Elizabeth P Howell, Gloria Broadwater, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
Pageof 24

Showing results (61-70 of 239) with videos related to

Sort By:
Pageof 24
Cancer Chemotherapy and Pharmacology|January 26, 2019
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancerKathleen Moore, John K Chan, Angeles Alvarez Secord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 14, 2013
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancerAngeles Alvarez Secord, Jason Cory Barnett, Jonathan A Ledermann, et al.
Cancer|August 8, 2013
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancerJason C Barnett, Angeles Alvarez Secord, David E Cohn, et al.
Gynecologic Oncology|September 28, 2018
Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysisStephanie L Lim, Haley A Moss, Angeles Alvarez Secord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2024
Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort studyNguyen Thao Thi Nguyen, Nicole Diaz, Hadley Reid, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 24, 2018
Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care ReferralsJonathan Foote, Micael Lopez-Acevedo, Gregory Samsa, et al.
Gynecologic Oncology|April 22, 2004
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancerLaura J Havrilesky, Charles A Leath, Warner Huh, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|May 14, 2023
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry scoreJulia M Moyett, Elizabeth P Howell, Gloria Broadwater, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
Pageof 24